Indication: Prostate Cancer
Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer
Metastatic (Stage IV)
Sub-indication: Biomarker study of DNA-repair Defects in Men With Metastatic Prostate Cancer
Line of Therapy: Metastatic Prostate Cancer
Principal Investigator: Dan Ishihara, M.D.
Sponsor: Janssen Research & Development
Email for more information: GU-NCIResearch@nortonhealthcare.org